文献速递结核与非结核分枝杆菌

免疫功能低下个体中不确定的干扰素-γ释放试验结果进展为活动性结核的风险:系统综述与荟萃分析

Risk of progression to active tuberculosis for indeterminate interferon-gamma release assay in immunocompromised individuals: a systematic review and meta-analysis.
PubMed 文献 · Clin Microbiol Infect · 2023-07-06

该系统综述与荟萃分析检索多个数据库,纳入28项研究共14792例免疫功能低下个体,评估潜伏性结核感染筛查中不确定的干扰素-γ释放试验(IGRA)结果进展为活动性结核的风险。结果显示,未治疗的不确定IGRA者累积发病率进展风险约为阳性者的0.51倍、阴性者的2.94倍,提示不确定结果可能代表中等进展风险,需适当随访管理。

要点

  • 不确定IGRA者累积发病进展风险为阳性者的0.51倍(95%CI 0.32-0.82)。
  • 不确定IGRA者累积发病进展风险为阴性者的2.94倍(95%CI 1.78-4.85)。
  • 人年发病率结果与累积发病率结果一致,支持结论可靠性。

核心结论

  • 免疫功能低下个体中不确定的IGRA结果可能代表进展为活动性结核的中等风险,约为阳性结果风险的一半、阴性结果风险的三倍。
  • 对不确定结果患者进行适当随访和管理对降低进展风险和改善患者结局至关重要。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase、Web of Science和Cochrane Library,检索截止2023年4月18日,无起始日期和语言限制。
  • 纳入队列研究或随机对照试验,评估潜伏性结核感染筛查中不确定IGRA进展为活动性结核的风险。
  • 共纳入28项研究,包含14792例免疫功能低下个体;采用固定效应荟萃分析获得两个合并风险比(RR)。
  • 偏倚风险评估采用改良版纽卡斯尔-渥太华量表。
  • RR-ip表示未治疗的不确定IGRA者 versus 阳性IGRA者的疾病进展率;RR-in表示未治疗的不确定IGRA者 versus 阴性IGRA者的疾病进展率。

主要发现

  • 累积发病率:不确定IGRA者 versus 阳性IGRA者的合并RR-ip为0.51(95%CI 0.32-0.82;I²=0%)。
  • 累积发病率:不确定IGRA者 versus 阴性IGRA者的合并RR-in为2.94(95%CI 1.78-4.85;I²=0%)。
  • 人年发病率:不确定IGRA者 versus 阳性IGRA者的合并RR-ip为0.40(95%CI 0.19-0.82;I²=13%)。
  • 人年发病率:不确定IGRA者 versus 阴性IGRA者的合并RR-in为2.67(95%CI 1.24-5.79;I²=23%)。
  • 共11项研究报告人年数据,用于验证累积发病率结果的可靠性。

关键数值与推荐

  • 不确定IGRA者累积发病进展风险为阳性者的0.51倍(95%CI 0.32-0.82)。
  • 不确定IGRA者累积发病进展风险为阴性者的2.94倍(95%CI 1.78-4.85)。
  • 不确定IGRA者人年发病进展风险为阳性者的0.40倍(95%CI 0.19-0.82)。
  • 不确定IGRA者人年发病进展风险为阴性者的2.67倍(95%CI 1.24-5.79)。

临床怎么用

  • 作者认为,对不确定IGRA结果的免疫功能低下患者进行适当随访和管理至关重要,以降低进展风险和改善患者结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist on assessing the risk of active tuberculosis (TB) in immunocompromised individuals during screening for latent tuberculosis infection (LTBI). OBJECTIVES: To assess the risk of progression to active TB for indeterminate interferon-γ release assays (IGRA) results in immunocompromised individuals during screening for LTBI. DATA SOURCES: PubMed, Embase, Web of Science, and the Cochrane Library were searched without start date or language restrictions on 18 April 2023. STUDY ELIGIBILITY CRITERIA: Cohort study or randomized controlled trials that investigated the risk of progression to active TB for indeterminate IGRA during LTBI screening. PARTICIPANTS: Immunocompromised individuals. TEST: IGRA (T-SPOT.TB and QuantiFERON). REFERENCE STANDARD: None. ASSESSMENT OF RISK OF BIAS: A modified version of the Newcastle-Ottawa Scale. METHODS OF DATA SYNTHESIS: Fixed effects meta-analysis was used to obtain two pooled risk ratios (RRs). RR-ip represented disease progression rate in untreated individuals with indeterminate IGRA versus positive IGRA. RR-in represented disease progression rate in untreated individuals with indeterminate IGRA versus negative IGRA. RESULTS: Among the 5102 identified studies, 28 (14 792 immunocompromised individuals) were included. The pooled RR-ip and RR-in for cumulative incidence were 0.51 (95% CI, 0.32-0.82; I2 = 0%) and 2.94 (95% CI, 1.78-4.85; I2 = 0%), respectively. In addition, 11 studies reporting person-year data were included to verify the reliability of cumulative incidence results. The pooled RR-ip and RR-in for person-year incidence were 0.40 (95% CI, 0.19-0.82; I2 = 13%) and 2.67 (95% CI, 1.24-5.79; I2 = 23%), respectively. DISCUSSION: Indeterminate IGRA results in immunocompromised individuals may represent an intermediate risk of progression to active TB, with half the risk for positive results and three times for negative results. Proper follow-up and management of patients with indeterminate results are crucial for mitigating progression risk and improving patient outcomes.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Zhou G, Luo S, He J, et al. Risk of progression to active tuberculosis for indeterminate interferon-gamma release assay in immunocompromised individuals: a systematic review and meta-analysis. Clin Microbiol Infect. 2023. PMID: 37422080. doi:10.1016/j.cmi.2023.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。